Fusion Antibodies PLC
LSE:FAB
P/FCFE
Price to FCFE
Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | P/FCFE | ||||
---|---|---|---|---|---|
UK |
Fusion Antibodies PLC
LSE:FAB
|
3.2m GBP | -1.4 | ||
US |
Thermo Fisher Scientific Inc
NYSE:TMO
|
220.9B USD | 40.5 | ||
US |
Danaher Corp
NYSE:DHR
|
182.8B USD | 49.3 | ||
US |
IQVIA Holdings Inc
NYSE:IQV
|
40.3B USD | 22.6 | ||
US |
Agilent Technologies Inc
NYSE:A
|
40.3B USD | 35.1 | ||
CH |
Lonza Group AG
SIX:LONN
|
37.1B CHF | 135 | ||
KR |
Samsung Biologics Co Ltd
KRX:207940
|
55.2T KRW | -448.6 | ||
US |
Mettler-Toledo International Inc
NYSE:MTD
|
26.9B USD | 32.5 | ||
US |
West Pharmaceutical Services Inc
NYSE:WST
|
26.9B USD | 70.1 | ||
IE |
ICON PLC
NASDAQ:ICLR
|
24.9B USD | 149.5 | ||
FR |
Sartorius Stedim Biotech SA
PAR:DIM
|
19B EUR | 11.3 |
P/FCFE Forward Multiples
Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.